{"nctId":"NCT01802385","briefTitle":"Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis","startDateStruct":{"date":"2015-03-09","type":"ACTUAL"},"conditions":["Cryptococcal Meningitis","Fungal Meningitis"],"count":460,"armGroups":[{"label":"Placebo","type":"NO_INTERVENTION","interventionNames":[]},{"label":"Sertraline 400mg","type":"EXPERIMENTAL","interventionNames":["Drug: Sertraline"]}],"interventions":[{"name":"Sertraline","otherNames":["Zoloft","Lustral"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Cryptococcal meningitis diagnosed by CSF cryptococcal antigen (CRAG)\n* HIV-1 infection\n* Ability and willingness of the participant or legal guardian/representative to provide informed consent\n* Willing to receive protocol-specified lumbar punctures\n\nExclusion Criteria:\n\n* Age \\< 18 years\n* Receipt of \\>=3 doses of amphotericin therapy\n* Cannot or unlikely to attend regular clinic visits\n* History of known liver cirrhosis\n* Presence of jaundice\n* Pregnancy\n* Current breastfeeding","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Survival","description":"18-week survival. The comparison will be between sertraline 400mg group and placebo","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"125","spread":null},{"groupId":"OG001","value":"109","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety (Occurence of Adverse Events)","description":"Safety and tolerability of adjunctive sertraline (grade 4-5) adverse reactions","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":null},{"groupId":"OG001","value":"141","spread":null}]}]}]},{"type":"SECONDARY","title":"Count of Participants With Cerebrospinal Fluid Sterility","description":"Number of participants with sterile cerebrospinal fluid at 2 weeks","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Center for Epidemiologic Studies in Depression (CES-D) Scale","description":"Center for Epidemiologic Studies in Depression (CES-D) scale at 14 weeks. CES-D scores are based on a 20 item survey with total scores ranging from 0 to 60. Higher scores suggest a greater presence of depressive symptoms. A CES-D score of 16 or higher is interpreted to indicate a risk for depression.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.6","spread":null},{"groupId":"OG001","value":"13.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Quantitative Neurocognitive Performance Score (QNPZ-8)","description":"Quantitative neurocognitive performance Z-score (QNPZ-8) at 14 weeks. The QNPZ-8 is a mean score of testing of 8 neurocognitive domains. Eqach domain is scaled based on a Z-score where the mean = 0 for the HIV-negative Ugandan population, accounting for age and educational status. Each +1 unit is one standard deviation better than the population norm. Each -1 unit is one standard deviation worse than the population norm.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":null},{"groupId":"OG001","value":"-1.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Fungal Clearance as Determined by Early Fungicidal Activity of CDF","description":"To determine whether adjunctive sertraline will lead to a faster rate of fungal clearance from cerebrospinal fluid (CSF), as measured by early fungicidal activity (EFA) of clearance of the Cryptococcus colony forming units (cfu) per mL of CSF per day, compared to standard therapy alone.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":null},{"groupId":"OG001","value":".43","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":null},{"groupId":"OG001","value":".33","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Experiencing IRIS OR Relapse","description":"Cumulative incidence of central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Event Free Survival","description":"Event free survival of composite events of: death,central nervous system (CNS) cryptococcal-related paradoxical immune reconstitution inflammatory syndrome (IRIS) or culture-positive relapse.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":121,"n":231},"commonTop":["Non-serious Adverse Events"]}}}